Literature DB >> 11686651

COWAT metanorms across age, education, and gender.

A S Loonstra1, A R Tarlow, A H Sellers.   

Abstract

Norms for the Controlled Oral Word Association Test (COWAT; Benton & Hamsher, 1976) have been published as summary statistics from many relatively small samples. The purpose of this study was to combine statistics from these samples to produce metanorms broken down by age, gender, and level of education. Means and standard deviations of letters F, A, and S (FAS) totals from normative samples and samples of normal controls were gathered from a wide variety of research studies and then stringently selected based on factors such as adequacy of the sample and presence of the appropriate statistics. The resulting aggregate statistics for FAS totals suggest differences may exist in verbal fluency task performance, depending on a person 's age, gender, and level of education.

Entities:  

Mesh:

Year:  2001        PMID: 11686651     DOI: 10.1207/S15324826AN0803_5

Source DB:  PubMed          Journal:  Appl Neuropsychol        ISSN: 0908-4282


  78 in total

1.  fNIRS suggests increased effort during executive access in ecstasy polydrug users.

Authors:  C A Roberts; C Montgomery
Journal:  Psychopharmacology (Berl)       Date:  2014-11-14       Impact factor: 4.530

Review 2.  A four-component model of age-related memory change.

Authors:  M Karl Healey; Michael J Kahana
Journal:  Psychol Rev       Date:  2015-10-26       Impact factor: 8.934

3.  Sex-Related Cognitive Profile in Autism Spectrum Disorders Diagnosed Late in Life: Implications for the Female Autistic Phenotype.

Authors:  Fritz-Georg Lehnhardt; Christine Michaela Falter; Astrid Gawronski; Kathleen Pfeiffer; Ralf Tepest; Jeremy Franklin; Kai Vogeley
Journal:  J Autism Dev Disord       Date:  2016-01

4.  Category and letter verbal fluency across the adult lifespan: relationship to EEG theta power.

Authors:  Adam M Brickman; Robert H Paul; Ronald A Cohen; Leanne M Williams; Kristin L MacGregor; Angela L Jefferson; David F Tate; John Gunstad; Evian Gordon
Journal:  Arch Clin Neuropsychol       Date:  2005-07       Impact factor: 2.813

5.  Quantifying talk: developing reliable measures of verbal productivity.

Authors:  Margaret Wardle; Katherine Cederbaum; Harriet de Wit
Journal:  Behav Res Methods       Date:  2011-03

6.  Syndromes dominated by apraxia of speech show distinct characteristics from agrammatic PPA.

Authors:  Keith A Josephs; Joseph R Duffy; Edythe A Strand; Mary M Machulda; Matthew L Senjem; Val J Lowe; Clifford R Jack; Jennifer L Whitwell
Journal:  Neurology       Date:  2013-06-26       Impact factor: 9.910

7.  Clinical and imaging progression over 10 years in a patient with primary progressive apraxia of speech and autopsy-confirmed corticobasal degeneration.

Authors:  Katerina A Tetzloff; Joseph R Duffy; Edythe A Strand; Mary M Machulda; Sarah M Boland; Rene L Utianski; Hugo Botha; Matthew L Senjem; Christopher G Schwarz; Keith A Josephs; Jennifer L Whitwell
Journal:  Neurocase       Date:  2018-05-25       Impact factor: 0.881

8.  Improving clinical cognitive testing: report of the AAN Behavioral Neurology Section Workgroup.

Authors:  Kirk R Daffner; Seth A Gale; A M Barrett; Bradley F Boeve; Anjan Chatterjee; H Branch Coslett; Mark D'Esposito; Glen R Finney; Darren R Gitelman; John J Hart; Alan J Lerner; Kimford J Meador; Alison C Pietras; Kytja S Voeller; Daniel I Kaufer
Journal:  Neurology       Date:  2015-07-10       Impact factor: 9.910

9.  Rapid eye movement sleep mediates age-related decline in prospective memory consolidation.

Authors:  Michael K Scullin; Chenlu Gao; Paul Fillmore; R Lynae Roberts; Natalya Pruett; Donald L Bliwise
Journal:  Sleep       Date:  2019-06-11       Impact factor: 5.849

10.  Clinical Progression in Four Cases of Primary Progressive Apraxia of Speech.

Authors:  Rene L Utianski; Joseph R Duffy; Heather M Clark; Edythe A Strand; Sarah M Boland; Mary M Machulda; Jennifer L Whitwell; Keith A Josephs
Journal:  Am J Speech Lang Pathol       Date:  2018-11-21       Impact factor: 2.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.